HealthNews

Nationwide recall alert: Pill bottle mix-up could lead to serious reactions

A pharmaceutical company is recalling one of its products after discovering that the pill bottle could be filled with the wrong medication.

According to the Food and Drug Administration (FDA), Unichem Pharmaceuticals is recalling its Cyclobenzaprine Hydrochloride Tablets USP 10 milligrams because the bottle was mistakenly filled with Meloxicam 7.5 milligrams tablets.

Meloxicam is a non-steroidal anti-inflammatory drug used to treat pain from conditions like osteoarthritis, rheumatoid arthritis and juvenile rheumatoid arthritis.

Cyclobenzaprine Hydrochloride is a muscle relaxer prescribed for muscle spasms.

Unknowingly taking Meloxicam can lead to serious side effects including heart and stomach problems, kidney issues and allergic reactions. This is particularly risky for patients already on non-steroidal anti-inflammatory drugs, blood thinners or those with underlying illnesses or allergies to Meloxicam.

The physical differences between the two drugs are that Meloxicam tablets are light yellow with a round flat beveled edge and has “U & L” imprinted on one side and “7.5″ debossed centrally on the other side.

Meanwhile, Cyclobenzaprine are blue biconvex tablets that are film coated, round shaped and have a “U” on one side and “12″ on the other side.

The mislabeled bottles can be identified by the lot number GMML24026A with the expiration date, September 2027 and NDC 29300-415-19 printed on the label of the 90-count bottles.

Unichem Pharmaceuticals has not received any reports of adverse events related to the recalled product. However, customers are asked to return the medication to the pharmacy they received their prescription from.

People who have experienced any issues that could be related to taking or using this drug product should contact their physician or healthcare provider.

See also  CM Revanth launches AIG Hospitals’ 300-bed multispecialty facility at Banjara Hills

If you purchase a product or register for an account through a link on our site, we may receive compensation. By using this site, you consent to our User Agreement and agree that your clicks, interactions, and personal information may be collected, recorded, and/or stored by us and social media and other third-party partners in accordance with our Privacy Policy.


Source link

Back to top button
close